Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae388 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Chandrasekaran Padmapriyadarsini und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India. Hauptthemen laut MEDLINE: Linezolid, Diarylquinolines, Antitubercular Agents, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: World Health Organization, United States Agency for International Development, US Agency for International Development.
Abstract (Originalsprache)
Background
Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration. We determined the effectiveness and safety of structured dose reduction of linezolid with bedaquiline and pretomanid in adults with pre–extensively drug-resistant (pre-XDR) or treatment-intolerant/nonresponsive multidrug-resistant (MDRTI/NR) pulmonary tuberculosis.
Method
Adults with pre-XDR or MDRTI/NR pulmonary tuberculosis were enrolled in a multicenter, parallel-group, randomized clinical trial in India. Patients were randomized to 26 weeks of bedaquiline, pretomanid, and daily linezolid, at 600 mg for 26 weeks (arm 1); 600 mg for 9 weeks followed by 300 mg for 17 weeks (arm 2); or 600 mg for 13 weeks followed by 300 mg for 13 weeks (arm 3). Study end points included sustained cure, bacteriological failure, toxicity, and death.
Results
Of 403 patients enrolled, 255 (63%) were <30 years old, 273 (68%) had prior tuberculosis episodes, and 238 (59%) were malnourished. At the end of treatment, after excluding those with negative baseline cultures, cure was seen in 120 (93%), 117 (94%), and 115 (93%) in arms 1, 2, and 3 respectively. Myelosuppression seen in 85 patients each in arms 1 and 2 and 77 patients in arm 3, not significantly different. Peripheral neuropathy was noticed in 66 patients (30, 17, and 19 in arms 1, 2, and 3) at 10–26 weeks (P = .02). The linezolid dose was reduced because of toxicity in 13, 2, and 4 patients in arms 1, 2, and 3, respectively.
Conclusions
In adults with pre-XDR or MDRTI/NR pulmonary tuberculosis, structured linezolid dose reduction to 300 mg/d is as effective as the standard 600-mg dose but with fewer cases of peripheral neuropathy when given with bedaquiline and pretomanid. Clinical Trials Registration Clinical Trial Registry of India (CTRI/2021/03/032189)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
- DRTB Site, Pandit Malviya Shatabdi Centenary Hospital, Mumbai, India.
- DRTB DOTS Plus Site, Sarvodaya Charitable Trust Hospital, Mumbai, India.
- Department of Epidemiology and Public Health, National Institute for Tuberculosis and Respiratory Diseases, New Delhi, India.
- Department of Pulmonary Medicine, Sarojini Naidu Medical College, Agra, India.
- Department of Respiratory Medicine, Government Medical College, Bhavnagar, India.
ORCID-Profile: Chandrasekaran Padmapriyadarsini
Förderung
- World Health Organization
- United States Agency for International Development
- US Agency for International Development
Zitieren
APA
Padmapriyadarsini, C., Oswal, V. S., Jain, C. D., Mariappan, M. V., Singla, N., Kumar, S., Daniel, B. D., Dave, J. D., Vadgama, P., Ramraj, B., Kant, S., Bhatnagar, A. K., Shanmugam, S., Paul, D., Bharathi, J., Palav, M., Shah, N. V., Santhanakrishnan, R., Dewan, R. K., …, & modified BPaL (mBPaL) Study Team (2024). Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae388
Vancouver
Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, et al. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae388
BibTeX
@article{Padmapriyadarsini2024,
author = {Padmapriyadarsini, Chandrasekaran and Oswal, Vikas S and Jain, Chetankumar D and Mariappan, Muthu Vijayalakshmi and Singla, Neeta and Kumar, Santosh and Daniel, Bella Devaleenal and Dave, Jigna D and Vadgama, Parul and Ramraj, Balaji and Kant, Surya and Bhatnagar, Anuj K and Shanmugam, Sivakumar and Paul, Dhamodharan and Bharathi, Jeyadeepa and Palav, Manasi and Shah, Neha V and Santhanakrishnan, Rameshkumar and Dewan, Ravindra K and Shekh, Nadim and Rathinam, Prabhakaran and Sisara, Arvind B and Mankar, Shubhangi Dhakulkar and Bajpai, Jyoti and Mittal, Upasana and Chauhan, Sandeep and Kumar, Ravinder and Parmar, Mallik and Mattoo, Sanjay K and Jaju, Jyoti and modified BPaL (mBPaL) Study Team, modified BPaL (mBPaL) Study Team},
title = {Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae388}
}
EUVIMED